Bacterial infections in cirrhosis: A growing problem with significant implications
Javier Fernandez, Vicente Arroyo – 21 June 2013 – Watch a video presentation of this article
Javier Fernandez, Vicente Arroyo – 21 June 2013 – Watch a video presentation of this article
Shih‐Wei Lai, Kuan‐Fu Liao – 21 June 2013 – Watch a video presentation of this article
Richard Moreau, Vicente Arroyo – 21 June 2013 – Watch a video presentation of this article
Javier Fernandez, Vicente Arroyo – 21 June 2013 – Watch a video presentation of this article
Manav Wadhawan, Subash Gupta, Neerav Goyal, Sunil Taneja, Ajay Kumar – 21 June 2013 – Hepatitis B immune globulin (HBIG) is routinely used in liver transplantation for hepatitis B virus (HBV)–related liver disease. With potent oral antivirals, HBIG may not be required. We conducted a prospective trial to evaluate living related liver transplantation (LRLT) without HBIG. Eighty‐nine patients with HBV‐related liver disease underwent LRLT between January 2005 and January 2012. All donors were vaccinated with the HBV vaccine.
Robert Perrillo, Maria Buti, Francois Durand, Michael Charlton, Adrian Gadano, Guido Cantisani, Che‐Chuan Loong, Kimberly Brown, Wenhua Hu, Juan Carlos Lopez‐Talavera, Cyril Llamoso – 21 June 2013 – For patients undergoing liver transplantation (LT) for hepatitis B virus (HBV)–related liver disease, the current standard of care for preventing reinfection of the allograft is nucleoside analogue therapy combined with hepatitis B immune globulin (HBIG).
Shih‐Wei Lai, Kuan‐Fu Liao – 21 June 2013 – Watch a video presentation of this article
Elsa Solà, Mónica Guevara, Pere Ginès – 21 June 2013 – Watch a video presentation of this article
Sumeet K. Asrani, Patrick S. Kamath – 21 June 2013 – Watch a video presentation of this article
Fasiha Kanwal, Hashem El‐Serag – 21 June 2013 – Watch a video presentation of this article